|
CRLX101 plus olaparib in patients with metastatic castration-resistant prostate cancer. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Boehringer Ingelheim (I); Janssen (I); Pfizer (I) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon |
Research Funding - Ambry Genetics (Inst); Bavarian Nordic (Inst); Johnson & Johnson (Inst); Sotio (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); EMD Serono (Inst); NantBioScience (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |